News

Cubist’s Sivextro gets FDA approval for serious skin infections

Cubist’s Sivextro gets FDA approval for serious skin infections

22-06-2014

The US Food and Drug Administration has approved Cubist Pharmaceuticals’ Sivextro (tedizolid phosphate)…

Antibiotics and Infectious diseasesCubist PharmaceuticalsPharmaceuticalRegulationSivextroUSA

Positive Ph III results with Cubist’s Sivextro in ABSSSI

Positive Ph III results with Cubist’s Sivextro in ABSSSI

06-06-2014

USA-based Cubist Pharmaceutical saw its share rise 3.1% to $70.80 in morning trading Friday, after the…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDermatologicalsPharmaceuticalResearchSivextro

Promising future for Cubist's Sivextro in anti-MRSA sector

04-04-2014

Following its launch, Cubist Pharmaceutical’s second generation oxazolidinone Sivextro Sivextro will…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDalvanceDurata TherapeuticsMarkets & MarketingoritavancinPharmaceuticalSivextroThe Medicines Company

Unanimous FDA advisory panel backing for Cubist’s Sivextro

Unanimous FDA advisory panel backing for Cubist’s Sivextro

02-04-2014

The US Food and Drug Administration’s Anti-Infective Drugs Advisory Committee on Monday voted unanimously…

Antibiotics and Infectious diseasesCubist PharmaceuticalsNorth AmericaPharmaceuticalRegulationSivextrotedizolidUSA

COMPANY SPOTLIGHT

Menarini

Back to top